CO2018013831A2 - Procesos para preparar oligómeros de morfolino fosforodiamidato - Google Patents

Procesos para preparar oligómeros de morfolino fosforodiamidato

Info

Publication number
CO2018013831A2
CO2018013831A2 CONC2018/0013831A CO2018013831A CO2018013831A2 CO 2018013831 A2 CO2018013831 A2 CO 2018013831A2 CO 2018013831 A CO2018013831 A CO 2018013831A CO 2018013831 A2 CO2018013831 A2 CO 2018013831A2
Authority
CO
Colombia
Prior art keywords
processes
oligomer
preparing
morpholino phosphorodiamidate
preparing morpholino
Prior art date
Application number
CONC2018/0013831A
Other languages
English (en)
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CO2018013831A2 publication Critical patent/CO2018013831A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyethers (AREA)

Abstract

La presente invención se refiere a procesos para preparar un oligómero (por ejemplo, un oligómero de morfolino). Los procesos sintéticos descritos en la presente pueden ser ventajosos para el escalar la síntesis de oligómeros mientras se mantiene el rendimiento general y pureza de un oligómero sintetizado.
CONC2018/0013831A 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato CO2018013831A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662341049P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/040311 WO2017205879A2 (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
CO2018013831A2 true CO2018013831A2 (es) 2018-12-28

Family

ID=64425889

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013831A CO2018013831A2 (es) 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato

Country Status (10)

Country Link
EP (1) EP3463389A4 (es)
JP (1) JP7022079B2 (es)
KR (1) KR102523522B1 (es)
CN (1) CN109152792B (es)
AU (1) AU2017270598B2 (es)
CA (1) CA3024153A1 (es)
CO (1) CO2018013831A2 (es)
MX (1) MX2018014160A (es)
SG (1) SG11201809502YA (es)
WO (1) WO2017205879A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
EP3657604A1 (en) 2018-11-26 2020-05-27 TE Connectivity Germany GmbH Cable terminating assembly with electrically insulating cutting blades
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
EP0433345B1 (en) 1988-09-01 1994-04-20 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
AU694157B2 (en) * 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
BR112012031363A2 (pt) * 2010-05-28 2021-10-26 Sarepta Therapeutcs, Inc Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais.
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP2623507B1 (en) 2010-09-30 2016-11-02 Nippon Shinyaku Co., Ltd. Morpholino nucleic acid derivative
EP2704749A1 (en) * 2011-05-05 2014-03-12 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2857664A1 (en) * 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy
EP2970963B1 (en) 2013-03-14 2019-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
RS58529B1 (sr) * 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
WO2014189142A1 (ja) * 2013-05-24 2014-11-27 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
WO2017205496A1 (en) * 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing oligomers
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
CN109152775B (zh) 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
KR20190024977A (ko) 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머

Also Published As

Publication number Publication date
EP3463389A4 (en) 2020-02-19
WO2017205879A3 (en) 2018-01-18
AU2017270598B2 (en) 2022-12-01
KR20190020674A (ko) 2019-03-04
CA3024153A1 (en) 2017-11-30
KR102523522B1 (ko) 2023-04-20
JP2019518748A (ja) 2019-07-04
EP3463389A2 (en) 2019-04-10
MX2018014160A (es) 2019-04-01
AU2017270598A1 (en) 2019-01-17
JP7022079B2 (ja) 2022-02-17
WO2017205879A2 (en) 2017-11-30
SG11201809502YA (en) 2018-12-28
CN109152792A (zh) 2019-01-04
CN109152792B (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2019002975A2 (es) Compuestos de tetraciclina y métodos de uso de los mismos
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
CO2019006018A2 (es) Polimorfos de sepiapterina y sus sales
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
SA518391776B1 (ar) تخليق انتقائي مزدوج التجاسم لمشتقات الفوسفات
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
DOP2016000211A (es) Pirazinas moduladoras de gpr6
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
NZ720106A (en) A process for the preparation of regadenoson
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CL2023000942A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso .
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.